On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s ABBV combination treatment for chronic ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...

There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

The FDA has approved AstraZeneca’s Calquence (acalabrutinib) for adults with chronic lymphocytic leukemia and small ...

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...

The researchers conducted a retrospective analysis of costs associated with hospitalization of CLL patients with serious infections.

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is one ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...